<h1>Company launches commercial 5-base sequencing kits for simultaneous variant and DNA methylation detection, raising IP and supply risks</h1> A genomic technology company announced a commercially available '5-base' sequencing solution enabling simultaneous detection of genomic variants and DNA methylation from a single sample, marketed as a scalable multiomic workflow compatible with its sequencing platforms and analytic pipeline. The product is offered in two kits (whole-genome and targeted enrichment) and relies on proprietary conversion chemistry and algorithms, raising IP and licensing considerations. The release includes forward-looking statements noting manufacturing, supply-chain, product performance, and customer acceptance risks that could affect commercial outcomes. Early-access research use was reported by an unnamed institute demonstrating potential utility in rare-disease research.